Home Retrotope Inc. (650) 437-0700 - Reinforcing the molecules of life to combat degenerative diseases

Reinforcing the Molecules of Life to Combat Degenerative Diseases

Human cells are continuously damaged by oxidative stress that is driven by lipid peroxidation (LPO). The resulting cellular degeneration contributes to a wide array of devasting degenerative diseases.

Retrotope is developing a pipeline of proprietary therapeutics designed to treat degenerative disease by down-regulating LPO in order to protect against cellular degeneration.

Science
of LPO

Development
Pipeline

Patient
Resources

OUR
MISSION

At Retrotope, we are pioneering the development of first-in-class therapies for devastating degenerative diseases - ranging from orphan neurodegenerative indications to large market degenerative conditions - for which there are few to no treatment options.

We are leveraging our proprietary drug discovery platform technology, along with our dedicated team of scientific leaders and industry veterans, to create novel, disease-modifying therapies designed to combat the oxidative stress and cellular degeneration that arise from lipid peroxidation.

Pipeline

Compound	Indication	Discovery/Preclinical	Phase I	Phase II	Phase III
RT001 Stabilized Linoleic Acid (LA, ethyl ester)	Infantile neuroaxonal dystrophy (INAD)
	Friedreich's ataxia (FA)
	Amyotrophic lateral sclerosis (ALS)
	Progressive supranuclear palsy (PSP)
RT011 Stabilized Docosahexaenoic acid (DHA, ethyl ester)	Dry Age-Related Macular Degeneration (Dry AMD) and geographic atrophy (GA)
Other stabilized PUFAs	Huntington’s disease (HD), Spinocerebellar ataxia (SCA) and Multiple system atropy (MSA)

NEWS & EVENTS

News

October 2021 - Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit

News

October 2021 - Retrotope Reports Data from Phase 2/3 Clinical Trial of RT001 and Concurrent Natural History Study in Patients with Infantile Neuroaxonal Dystrophy (INAD)

News

August 2021 - Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)

Press releases

June 2021 - Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)

Press releases

April 2021 - Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Press releases

March 2021 - Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit

Retrotope Reports Data from Phase 2/3 Clinical Trial of RT001 and Concurrent Natural History Study in Patients with Infantile Neuroaxonal Dystrophy (INAD)

Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)

First-in-Class, Oral Drug Candidate to be Evaluated in Randomized, Double-Blind, Placebo-Controlled Study in Patients with Debilitating Neurodegenerative Disease

The study’s enrollment target of 40 patients was exceeded in less than six weeks, highlighting the high demand for participation in the trial featuring a novel treatment approach for ALS. Based on this rapid patient enrollment, Retrotope expects...

The first patient was dosed on March 10, with an additional eight patients enrolled during the study’s first week. Clinical investigators have already reported additional patient interest beyond the 40 subjects planned for the trial. As such,...

Leadership